Discussing Pfizer's Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Executed on:Apr 22, 2026 9:15 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Dana-Farber Cancer Institute and Harvard Medical School Assistant Professor of Medicine at Harvard Medical School; Clinical Director of the Center for Cancer Therapeutic Innovation (Early Drug Development); Medical Director of the Breast Cancer Pathway at Dana-Farber
Treats hundreds of patients with metastatic and treatment-resistant breast cancer, including those enrolled in early-phase clinical trials at a leading academic cancer center 
Research focus on oncology drug development and metastatic breast cancer. Serves as Principal Investigator on multiple Phase 1 trials evaluating novel targeted therapies including CDK inhibitors, antibody-drug conjugates, and PI3K pathway agents. Research centers on mechanisms of resistance to CDK4/6 inhibitors, cell cycle biology, and biomarker-driven treatment strategies in HR+/HER2- metastatic breast cancer. Recognized with prestigious awards including the AACR–Bristol Myers Squibb Fellowship and ASCO Young Investigator Award, and actively contributes to advancing next-generation therapeutics in oncology

Interview Goal

To gain a deeper understanding of Atirmociclib (PF-07220060; Selective CDK4 Inhibitor) for Second-Line HR-Positive, HER2-Negative Metastatic Breast Cancer

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.